Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valiltramiprosate - Alzheon

Next Previous
Drug Profile

Valiltramiprosate - Alzheon

Alternative Names: ALZ 801; BLU-8499; NRM-8499; Tramiprosate prodrug - Alzheon

Latest Information Update: 10 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BELLUS Health
  • Developer Alzheon; BELLUS Health; National Institute on Aging
  • Class Alkanesulfonic acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Amyloid beta-peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Cerebral amyloid angiopathy; Down syndrome

Most Recent Events

  • 25 Jun 2026 Alzheon terminates the APOLLOE4-LTE phase III long-term extension trial for Alzheimer's disease (Early-stage disease) in USA, Canada and United Kingdom (PO, Tablet) due to sponsor business decision (NCT06304883)
  • 27 Jul 2025 Updated efficacy data from the phase III APOLLOE4 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
  • 27 Jul 2025 Updated adverse events data from the phase III APOLLOE4 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top